Searched for
REGENERON PHARMACEUTICALS
Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiativeRegeneron will reduce prices for its drugs on Medicaid. A cholesterol drug, Praluent, will be available for USD 225 on Trump's discounted d...
- Global Markets | Australian shares slide as US-Iran talks fail, risk appetite soursAustralian shares declined as collapsed U.S.-Iran peace talks and a U.S. blockade of Iranian ports soured market sentiment. The S&P/ASX 200...
- Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA dataSouth San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after a decline in c...
- Regeneron to rescue 23andMe from bankruptcy in $256 million deal — but who really owns your genetic data now and what happens to your DNA privacy?Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and what happens to ...
- Biocon Biologics secures market entry for Yesafili in USBiocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili...
- Biocon Biologics settles patent issue; paves way for launch of biosimilar product in CanadaBiocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalm...
- New project aims to set up world's largest African ancestry database for genetic studiesScientists are embarking on a project to collect genetic material from 500,000 people of African ancestry in order to create the world's la...
- Five Indian-American teenagers selected as finalists of prestigious science and maths competition in USAmong them, the five Indian American include Siddhu Pachipala from Texas, Lavanya Natarajan and Ishika Nag from Florida, Neel Moudgal from ...
- AstraZeneca says antibody treatment failed in preventing COVID-19 in exposed patientsThe company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the co...
- India's Zydus Cadila seeks human trial approval for COVID-19 antibody cocktailRegeneron and Roche's antibody cocktail has also received emergency use approval in India, and will be distributed by drugmaker Cipla. The ...
- Roche reports promising results from anti-Covid cocktailThe results of the Phase 3 trial showed that the combination of the antibodies casirivimab and imdevimab "reduced hospitalisation or death ...
- Canada pledges C$485 million in COVID-19 aid for other countriesThe money will enable the United Nations children's agency UNICEF to buy up to 3 million courses of antibody treatments once they are appro...
- Eli Lilly and Co to supply 650,000 more doses of COVID-19 drug to U.S. governmentThe new purchase is part of a U.S. government deal to secure nearly 1 million doses of Lilly's bamlanivimab, a treatment similar to Regener...
- 2nd study testing a COVID-19 antibody drug has a setbackTests in animals suggest that antibody drugs work best when given early in infection to lower the amount of virus, he said. Once someone is...
- Eli Lilly antibody drug fails in a COVID-19 study; others go onIndependent monitors had paused enrolment in the study two weeks ago because of a possible safety issue. But on Monday, the National Instit...
- US regulators approve 1st treatment for EbolaThe Food and Drug Administration OK'd the drug developed by Regeneron Pharmaceuticals for treating adults and children with the Zaire Ebola...
- What are antibody therapies and who is developing them for COVID-19?More recently, scientists have developed treatments called monoclonal antibodies -- antibodies that can be isolated and manufactured in lar...
- Sanofi and Regeneron's eczema drug gets FDA approvalThe FDA approved Dupixent (dupilumab), is the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis.
- Biocon among world's top pharma employers"The Biocon employer brand has been growing stronger with each passing year, and our increased success in attracting talent is a testimony ...
Load More
